Durability of recaptured response to ozanimod during the True North open-label extension

被引：0
|
作者：
Dignass, A. [1 ]
Regueiro, M. [2 ]
Colombel, J. F. [3 ]
Jain, A. [4 ]
Canavan, J. B. [4 ]
Wu, H. [4 ]
Lawlor, G. [4 ]
Osterman, M. T. [4 ]
Vermeire, S. [5 ]
Rubin, D. T. [6 ]
机构：
[1] Goethe Univ, Med, Agaples Markus Hosp, Frankfurt, Germany
[2] Cleveland Clin Cleveland, Digest Dis & Surg Inst, Cleveland, OH USA
[3] Icahn Sch Med Mt Sinai, Gastroenterol, New York, NY USA
[4] Bristol Myers Squibb, Clin Res, Princeton, NJ USA
[5] Univ Leuven, Chron Dis & Metab, Leuven, Belgium
[6] Univ Chicago, Gastroenterol, Chicago, IL USA
来源：
JOURNAL OF CROHNS & COLITIS | 2023年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P687
引用
收藏
页码：817 / 818
页数：2
相关论文
共 50 条
  • [1] Impact of prior biologic exposure on durability of recaptured response to ozanimod during the True North open-label extension study
    Colombel, J. F.
    Rubin, D. T.
    Vermeire, S.
    Jain, A.
    Canavan, J. B.
    Wu, H.
    Lawlor, G.
    Osterman, M. T.
    Dignass, A.
    Regueiro, R.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 738 - 739
  • [2] Cardiovascular Safety of Ozanimod in Patients With Ulcerative Colitis: True North and Open-Label Extension Analyses
    Armuzzi, Alessandro
    Cross, Raymond K.
    Lichtenstein, Gary R.
    Hou, Jason
    Deepak, Parakkal
    Regueiro, Miguel
    Wolf, Douglas C.
    Akukwe, Lucy
    Ahmad, Harris A.
    Jain, Anjali
    Kozinn, Marc
    Wu, Hsiuanlin
    Petersen, AnnKatrin
    Charles, Lorna
    Long, Millie
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2024, 22 (05) : 1067 - 1076.e3
  • [3] EXTENDED INDUCTION IN THE TRUE NORTH OPEN-LABEL EXTENSION STUDY: CLINICAL OUTCOMES OF ∼2 YEARS OF OZANIMOD TREATMENT
    Rubin, David T.
    Colombel, Jean Frederic
    Chiorean, Michael V.
    Ghosh, Subrata
    Jain, Anjali
    Lawlor, Garrett
    Osterman, Mark T.
    Wu, Hsiuanlin
    Canavan, James B.
    Vermeire, Severine
    GASTROENTEROLOGY, 2023, 164 (06) : S1102 - S1102
  • [4] Extended induction in the True North open-label extension study: clinical outcomes of ∼2 years of ozanimod treatment
    Vermeire, S.
    Colombel, J. F.
    Chiorean, M. V.
    Ghosh, S.
    Jain, A.
    Lawlor, G.
    Osterman, M. T.
    Wu, H.
    Canavan, J. B.
    Rubin, D. T.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 903 - 904
  • [5] Durability of Symptomatic and Clinical Outcomes in Ozanimod- Treated Patients by Endpoints of Increasing Objectivity at True North Week 52: Interim Analysis of the True North Open-Label Extension Study
    Abreu, Maria T.
    Panaccione, Remo
    Vermeire, Severine
    Rubin, David T.
    Mehra, Dimpy
    Wu, Hsiuanlin
    Osterman, Mark T.
    Ahmad, Harris A.
    Jain, Anjali
    Danese, Silvio
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S698 - S699
  • [6] Efficacy and safety of 3 years of continuous ozanimod treatment: an interim analysis of the True North open-label extension study
    Danese, S.
    Abreu, M. T.
    Wolf, D. C.
    Canavan, J. B.
    Jain, A.
    Wu, H.
    Petersen, A.
    Charles, L.
    Panaccione, R.
    Afzali, A.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : I101 - I102
  • [7] Efficacy and Safety of 2 Years of Continuous Ozanimod Treatment: Interim Analysis of the True North Open-Label Extension Study
    Abreu, Maria T.
    Dulai, Parambir
    Dignass, Axel
    Savarino, Edoardo
    Hudesman, David
    Afzali, Anita
    Jairath, Vipul
    Osterman, Mark
    Akukwe, Lucy
    Liu, W. Jerry
    Memaj, Arteid
    Petersen, AnnKatrin
    Jain, Anjali
    Canavan, James B.
    Vermeire, Severine
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S537 - S537
  • [8] Efficacy and safety of 3 years of continuous ozanimod treatment: An interim analysis of the True North open-label extension study
    Danese, S.
    Sparrow, M.
    Abreu, M. T.
    Wolf, D. C.
    Canavan, J. B.
    Jain, A.
    Wu, H.
    Petersen, A.
    Charles, L.
    Panaccione, R.
    Afzali, A.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2023, 38 : 121 - 122
  • [9] Efficacy and safety of 4 years of continuous ozanimod treatment: an interim analysis of the True North open-label extension study
    D'Haens, G.
    Sands, B. E.
    Ferrante, M.
    Matsuoka, K.
    Lindsay, J. O.
    Blumenstein, I.
    Mehra, D.
    Charles, L.
    Cetin, V.
    Petersen, A.
    Wu, H.
    Wang, D.
    Jain, A.
    Hanauer, S. B.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1814 - I1815
  • [10] DURABILITY OF RESPONSE IN DELAYED RESPONDERS TO OZANIMOD IN PATIENTS WITH ULCERATIVE COLITIS STRATIFIED BY NUMBER OF PRIOR BIOLOGICS: 3-YEAR UPDATE FROM THE TRUE NORTH OPEN-LABEL EXTENSION STUDY
    Regueiro, Miguel D.
    D'Haens, Geert
    Cross, Raymond K.
    Malter, Lisa
    Irving, Peter M.
    Wu, Hsiuanlin
    Lama, Sonie
    Lawlor, Garrett
    Osterman, Mark T.
    Jain, Anjali
    Dignass, Axel
    GASTROENTEROLOGY, 2024, 166 (05) : S815 - S815
12345